Cargando…

One‐stop microvascular screening service: an effective model for the early detection of diabetic peripheral neuropathy and the high‐risk foot

AIMS: To evaluate the feasibility of a one‐stop microvascular screening service for the early diagnosis of diabetic distal symmetrical polyneuropathy, painful distal symmetrical polyneuropathy and the at‐risk diabetic foot. METHODS: People with diabetes attending retinal screening in hospital and co...

Descripción completa

Detalles Bibliográficos
Autores principales: Binns‐Hall, O., Selvarajah, D., Sanger, D., Walker, J., Scott, A., Tesfaye, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033008/
https://www.ncbi.nlm.nih.gov/pubmed/29608799
http://dx.doi.org/10.1111/dme.13630
_version_ 1783337616493510656
author Binns‐Hall, O.
Selvarajah, D.
Sanger, D.
Walker, J.
Scott, A.
Tesfaye, S.
author_facet Binns‐Hall, O.
Selvarajah, D.
Sanger, D.
Walker, J.
Scott, A.
Tesfaye, S.
author_sort Binns‐Hall, O.
collection PubMed
description AIMS: To evaluate the feasibility of a one‐stop microvascular screening service for the early diagnosis of diabetic distal symmetrical polyneuropathy, painful distal symmetrical polyneuropathy and the at‐risk diabetic foot. METHODS: People with diabetes attending retinal screening in hospital and community settings had their feet examined by a podiatrist. Assessment included: Toronto Clinical Neuropathy Score evaluation; a 10‐g monofilament test; and two validated, objective and quick measures of neuropathy obtained using the point‐of‐care devices ‘DPN‐Check’, a hand‐held device that measures sural nerve conduction velocity and amplitude, and ‘Sudoscan’, a device that measures sudomotor function. The diagnostic utility of these devices was assessed against the Toronto Clinical Neuropathy Score as the ‘gold standard’. RESULTS: A total of 236 consecutive people attending the retinal screening service, 18.9% of whom had never previously had their feet examined, were evaluated. The prevalence of distal symmetrical polyneuropathy, assessed using the Toronto Clinical Neuropathy Score, was 30.9%, and was underestimated by 10‐g monofilament test (14.4%). The prevalence of distal symmetrical polyneuropathy using DPN‐check was 51.5% (84.3% sensitivity, 68.3% specificity), 38.2% using Sudoscan foot electrochemical skin conductance (77.4% sensitivity, 68.3% specificity), and 61.9% using abnormality in either of the results (93.2% sensitivity, 52.8% specificity). The results of both devices correlated with Toronto Clinical Neuropathy Score (P<0.001). A new diagnosis of painful distal symmetrical polyneuropathy was made in 59 participants (25%), and 56.6% had moderate‐ or high‐risk foot. Participants rated the service very highly. CONCLUSIONS: Combined, eye, foot and renal screening is feasible, has a high uptake, reduces clinic visits, and identifies painful distal symmetrical polyneuropathy and the at‐risk foot. Combined large‐ and small‐nerve‐fibre assessment using non‐invasive, quantitative and quick point‐of‐care devices may be an effective model for the early diagnosis of distal symmetrical polyneuropathy.
format Online
Article
Text
id pubmed-6033008
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-60330082018-07-12 One‐stop microvascular screening service: an effective model for the early detection of diabetic peripheral neuropathy and the high‐risk foot Binns‐Hall, O. Selvarajah, D. Sanger, D. Walker, J. Scott, A. Tesfaye, S. Diabet Med Research Articles AIMS: To evaluate the feasibility of a one‐stop microvascular screening service for the early diagnosis of diabetic distal symmetrical polyneuropathy, painful distal symmetrical polyneuropathy and the at‐risk diabetic foot. METHODS: People with diabetes attending retinal screening in hospital and community settings had their feet examined by a podiatrist. Assessment included: Toronto Clinical Neuropathy Score evaluation; a 10‐g monofilament test; and two validated, objective and quick measures of neuropathy obtained using the point‐of‐care devices ‘DPN‐Check’, a hand‐held device that measures sural nerve conduction velocity and amplitude, and ‘Sudoscan’, a device that measures sudomotor function. The diagnostic utility of these devices was assessed against the Toronto Clinical Neuropathy Score as the ‘gold standard’. RESULTS: A total of 236 consecutive people attending the retinal screening service, 18.9% of whom had never previously had their feet examined, were evaluated. The prevalence of distal symmetrical polyneuropathy, assessed using the Toronto Clinical Neuropathy Score, was 30.9%, and was underestimated by 10‐g monofilament test (14.4%). The prevalence of distal symmetrical polyneuropathy using DPN‐check was 51.5% (84.3% sensitivity, 68.3% specificity), 38.2% using Sudoscan foot electrochemical skin conductance (77.4% sensitivity, 68.3% specificity), and 61.9% using abnormality in either of the results (93.2% sensitivity, 52.8% specificity). The results of both devices correlated with Toronto Clinical Neuropathy Score (P<0.001). A new diagnosis of painful distal symmetrical polyneuropathy was made in 59 participants (25%), and 56.6% had moderate‐ or high‐risk foot. Participants rated the service very highly. CONCLUSIONS: Combined, eye, foot and renal screening is feasible, has a high uptake, reduces clinic visits, and identifies painful distal symmetrical polyneuropathy and the at‐risk foot. Combined large‐ and small‐nerve‐fibre assessment using non‐invasive, quantitative and quick point‐of‐care devices may be an effective model for the early diagnosis of distal symmetrical polyneuropathy. John Wiley and Sons Inc. 2018-05-10 2018-07 /pmc/articles/PMC6033008/ /pubmed/29608799 http://dx.doi.org/10.1111/dme.13630 Text en © 2018 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research Articles
Binns‐Hall, O.
Selvarajah, D.
Sanger, D.
Walker, J.
Scott, A.
Tesfaye, S.
One‐stop microvascular screening service: an effective model for the early detection of diabetic peripheral neuropathy and the high‐risk foot
title One‐stop microvascular screening service: an effective model for the early detection of diabetic peripheral neuropathy and the high‐risk foot
title_full One‐stop microvascular screening service: an effective model for the early detection of diabetic peripheral neuropathy and the high‐risk foot
title_fullStr One‐stop microvascular screening service: an effective model for the early detection of diabetic peripheral neuropathy and the high‐risk foot
title_full_unstemmed One‐stop microvascular screening service: an effective model for the early detection of diabetic peripheral neuropathy and the high‐risk foot
title_short One‐stop microvascular screening service: an effective model for the early detection of diabetic peripheral neuropathy and the high‐risk foot
title_sort one‐stop microvascular screening service: an effective model for the early detection of diabetic peripheral neuropathy and the high‐risk foot
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033008/
https://www.ncbi.nlm.nih.gov/pubmed/29608799
http://dx.doi.org/10.1111/dme.13630
work_keys_str_mv AT binnshallo onestopmicrovascularscreeningserviceaneffectivemodelfortheearlydetectionofdiabeticperipheralneuropathyandthehighriskfoot
AT selvarajahd onestopmicrovascularscreeningserviceaneffectivemodelfortheearlydetectionofdiabeticperipheralneuropathyandthehighriskfoot
AT sangerd onestopmicrovascularscreeningserviceaneffectivemodelfortheearlydetectionofdiabeticperipheralneuropathyandthehighriskfoot
AT walkerj onestopmicrovascularscreeningserviceaneffectivemodelfortheearlydetectionofdiabeticperipheralneuropathyandthehighriskfoot
AT scotta onestopmicrovascularscreeningserviceaneffectivemodelfortheearlydetectionofdiabeticperipheralneuropathyandthehighriskfoot
AT tesfayes onestopmicrovascularscreeningserviceaneffectivemodelfortheearlydetectionofdiabeticperipheralneuropathyandthehighriskfoot